三生制药(01530.HK)向辉瑞(PFE.US)授出产品独家许可及发行1亿美元新股 股价飙逾三成

阿斯达克财经
May 20

三生制药(01530.HK) 今早高开14.9%,最高见22元。现报19元,升31.03%,成交4,433万股,涉资8.34亿元。

三生制药宣布与辉瑞(PFE.US)  签订独家许可协议,将向辉瑞授予在中国内地以外的全球地区开发、生产、商业化其产品PD-1/VEGF双特异性抗体(SSGJ-707)的独家许可,许可首付款及潜在里程碑合计高达60.5亿美元。另外辉瑞拟斥1亿美元认购三生制药配发的新股份。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-19 16:25。) (美股为即时串流报价; OTC市场股票除外,资料延迟最少15分钟。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10